SCHEMBL1003228

SCHEMBL1003228

CC=CC(CCC)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.46
AKR1A1 P14550 1/20 0.46
CHRM3 P20309 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
ADRA1A P35348 1/20 0.46
HRH1 P35367 1/20 0.46
DRD3 P35462 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HDAC7 Q8WUI4 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
GRIK1 P39086 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38662397 1.00 CHRM1 (0.46) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL1003227 1.00 CHRM1 (0.46) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL8488815 0.87 CA2 (0.47) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL1474367 0.87 CA2 (0.47) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL2963668 0.87 CA2 (0.47) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL2962104 0.85 GPR84 (0.48) GRIK1SLC1A2SLC1A1GRIK2CA2
SCHEMBL868772 0.85 GPR84 (0.48) GRIK1SLC1A2SLC1A1GRIK2CA2
SCHEMBL5331357 0.84 GPR84 (0.52) GRIK1SLC1A2SLC1A1GRIK2GPR84
SCHEMBL5047820 0.84 GPR84 (0.52) GRIK1SLC1A2SLC1A1GRIK2GPR84
SCHEMBL5331360 0.84 GPR84 (0.52) GRIK1SLC1A2SLC1A1GRIK2GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117129590-A Application of endogenous metabolite in preparation of aplastic anemia diagnosis product 苏州派博思生物技术有限公司 2023-11-28 CN claimed
CN-117129590-A Application of endogenous metabolite in preparation of aplastic anemia diagnosis product 苏州派博思生物技术有限公司 2023-11-28 CN disclosed
CN-115812710-A Insect repellent composition comprising one or more insect repellent fatty acids having 9 to 21 carbon atoms 长荣置地有限公司 2023-03-21 CN disclosed
CN-112118739-B Insect repellent composition comprising one or more insect repellent fatty acids having 9 to 21 carbon atoms 长荣置地有限公司 2023-01-10 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-112118739-A Insect repellent composition comprising one or more insect repellent fatty acids having 9 to 21 carbon atoms 长荣置地有限公司 2020-12-22 CN disclosed
US-20190391092-A1 METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) Oregon Institute of Science and Medicine 2019-12-26 US disclosed
US-8367792-B2 Polysiloxane compound and method of producing the same JNC CORPORATION (JP) 2013-02-05 US disclosed
US-20120208973-A1 POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME OOTAKE NOBUMASA (JP) 2012-08-16 US disclosed
EP-2456433-A2 METHODS FOR THE PREPARATION AND USE OF AQUEOUS SOLUTIONS OF MAGNESIUM VALPROATE HYDRATE AND L-CARNITINE Biolink Life Sciences, Inc. (US) 2012-05-30 EP disclosed
EP-0659172-A1 ANALOGUES OF VPA USED AS ANTI-EPILEPTICA. NAU HEINZ (DE) 1995-06-28 EP disclosed
EP-0632008-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1995-01-04 EP disclosed
WO-1994006743-A1 ANALOGUES OF VPA USED AS ANTI-EPILEPTICA NAU HEINZ (DE) 1994-03-31 WO disclosed
US-4966996-A Process for the preparation of E-2-propyl-2-pentenoic acid and physiologically compatible salts thereof Desitin Arznemittel GmbH (DE) 1990-10-30 US disclosed
EP-0293753-A2 Process for preparing E-2-propyl-2-pentenoic acid and its physiologically compatible salts Desitin Arzneimittel GmbH (DE) 1988-12-07 EP disclosed
EP-0043285-B2 METHOD FOR DETERMINATION OF VALPROIC ACID AND REAGENTS THEREIN Dainippon Pharmaceutical Co., Ltd. (JP) 1988-06-22 EP disclosed
US-4443365-A Method for determination of the valproic acid and reagents therein DAINIPPON PHARMACEUTICAL COMPANY LIMITED (JP) 1984-04-17 US disclosed
US-4432985-A N-alkylated carboxylic acid derivatives as anti-convulsant agents ABBOTT LABORATORIES (US) 1984-02-21 US disclosed
EP-0043285-B1 METHOD FOR DETERMINATION OF VALPROIC ACID AND REAGENTS THEREIN Dainippon Pharmaceutical Co., Ltd. (JP) 1984-01-04 EP disclosed
EP-0043285-A1 Method for determination of valproic acid and reagents therein Dainippon Pharmaceutical Co., Ltd. (JP) 1982-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208973-A1 POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME RPS4X, POLR2A, MSL1 CHRM1 463/4885AKR1A1 2078/4885CHRM3 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.